Financial Performance - The company's revenue for Q1 2025 was ¥71,052,156.02, a decrease of 21.20% compared to ¥90,172,342.02 in the same period last year[5] - Net profit attributable to shareholders was ¥11,849,289.05, down 60.09% from ¥29,687,084.26 year-on-year[5] - Basic earnings per share decreased by 60.00% to ¥0.18 from ¥0.45 in the previous year[5] - The company reported a 76.44% decrease in net profit after deducting non-recurring gains and losses, amounting to ¥5,358,872.31 compared to ¥22,744,459.46 in the same period last year[5] - Total operating revenue for the current period is ¥71,052,156.02, a decrease of 21.2% compared to ¥90,172,342.02 in the previous period[23] - Net profit for the current period is ¥11,849,289.05, down 60.0% from ¥29,687,084.26 in the previous period[24] - Operating profit decreased significantly to ¥11,769,736.76 from ¥32,127,485.39, a decline of 63.4%[24] - Total comprehensive income for the period was CNY 11,849,289.05, compared to CNY 29,687,084.26 in the previous period[25] - Basic and diluted earnings per share were both CNY 0.18, down from CNY 0.45 in the previous period[25] Cash Flow - The net cash flow from operating activities was -¥16,868,485.59, a significant decline of 3,079.21% compared to ¥566,206.01 in Q1 2024[5] - Cash inflow from operating activities totaled CNY 55,460,356.38, down from CNY 77,696,322.08 in the previous period[27] - Cash outflow from operating activities was CNY 72,328,841.97, compared to CNY 77,130,116.07 in the previous period[28] - Cash flow from investing activities generated a net inflow of CNY 16,193,260.48, compared to a net outflow of CNY -15,317,843.65 in the previous period[28] - Cash and cash equivalents at the end of the period were CNY 151,823,897.33, down from CNY 238,745,336.87 at the end of the previous period[28] - Total cash inflow from investment activities was CNY 690,905,762.96, with cash outflow of CNY 674,712,502.48[28] - The company did not report any cash inflow from financing activities during the period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,576,204,060.70, down 1.72% from ¥1,603,808,014.06 at the end of the previous year[5] - The company’s total liabilities decreased by 1.04% to ¥1,497,621,339.19 from ¥1,513,368,506.60 at the end of the previous year[5] - Total liabilities decreased to ¥78,582,721.51 from ¥90,439,507.46, a reduction of 13.1%[22] - The company reported a decrease in accounts payable, which rose to ¥39,620,377.34 from ¥37,833,222.06, an increase of 4.7%[22] - The company's cash and cash equivalents decreased from ¥179,294,435.57 to ¥151,823,897.33, representing a decline of approximately 15.3%[20] - The trading financial assets slightly decreased from ¥1,023,470,174.93 to ¥1,006,075,052.63, a reduction of about 1.7%[20] - Accounts receivable increased from ¥63,892,072.37 to ¥67,744,481.69, showing a growth of approximately 6.0%[20] - The prepayments rose from ¥9,942,873.55 to ¥10,840,590.77, indicating an increase of around 9.0%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,256[14] - The company has a total of 44,243,675 shares under lock-up, with the majority set to be released on March 25, 2027[18] - The top shareholder, Tao Chunlei, holds 26,427,800 shares, which are subject to lock-up until March 25, 2027[17] - The company reported no changes in the number of restricted shares during the period[17] - The top ten shareholders include significant holdings from various investment partnerships, indicating a diverse ownership structure[18] Operational Insights - The company experienced a significant increase in investment income, which rose by 216.37% to ¥2,149,076.26 from ¥679,300.01 year-on-year[11] - The cash flow from investing activities improved to ¥16,193,260.48, a 205.72% increase compared to -¥15,317,843.65 in Q1 2024[13] - Research and development expenses for the current period are ¥10,765,309.15, slightly up from ¥10,738,916.39 in the previous period[24] - Deferred income tax liabilities increased slightly to ¥8,371,304.41 from ¥8,310,227.58, an increase of 0.7%[22] - The company has not engaged in any new mergers or acquisitions during the reporting period[19] - There are no new product launches or technological advancements reported in the latest earnings call[19] Audit Status - The first quarter report was not audited[29]
万邦医药(301520) - 2025 Q1 - 季度财报